French DRG (diagnosis-related group) ratings threaten innovative/orthopaedic products
This article was originally published in Clinica
Executive Summary
The French medical device industry is lobbying the government to ensure that the new diagnosis-related group (DRG) scheme, known locally at the T2A system, does not drive payments for devices so low that there is no possibility of using innovative products. Medical professionals will need to retain the option of having access to such products, or those that offer additional benefits, for example in terms of patient recovery time or comfort.